All In Biotech

NDA 021305 · Jubilant

Hicon

Sodium Iodide I-131 · Oral

Last checked: Nov 19, 2026Latest source record: Jun 11, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2003

Jan 24, 2003

Approved uses

2

Original approval plus efficacy supplements

Registered trials

190

30 Phase 3, 19 recruiting

FAERS reports

960

900 serious, 46 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 21, 2025.

HICON ® is indicated for the treatment of hyperthyroidism and selected cases of thyroid carcinoma. HICON ® is a radioactive therapeutic agent indicated for the treatment of hyperthyroidism and selected cases of carcinoma of the thyroid.

Mechanism: Iodide is actively transported by the sodium-iodide symporter (NIS) protein, in thyroid follicular cells. Iodide is concentrated in follicular cells to levels up to 50 times higher than in the plasma. Iodide is metabolically oxidized by thyroid peroxidase to iodinium (I + ) which in turn iodinates tyrosine residues of thyroglobulin (tri or tetra-iodinated tyrosine). The beta emission of I 131 is responsible for the therapeutic effect.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

6 products under this application
  • HICON · SODIUM IODIDE I-131 250-1000mCi · SOLUTION, ORAL · Prescription · TE AA
  • HICON · SODIUM IODIDE I-131 1-1000mCi/ML · SOLUTION, ORAL · Discontinued
  • HICON · SODIUM IODIDE I-131 1-500mCi/0.5ML · SOLUTION, ORAL · Discontinued
  • SODIUM IODIDE I 131 · SODIUM IODIDE I-131 0.009-0.1mCi · CAPSULE, ORAL · Prescription
  • SODIUM IODIDE I 131 · SODIUM IODIDE I-131 2-200mCi · CAPSULE, ORAL · Discontinued
  • HICON · SODIUM IODIDE I-131 1-250mCi/0.25ML · SOLUTION, ORAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Iodide I-131" as an intervention, any sponsor and status, largest first.

All 190 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • hypothyroidism385
  • endocrine ophthalmopathy36
  • treatment failure26
  • acute myeloid leukaemia24
  • dacryostenosis acquired24
  • hyperthyroidism23
  • parathyroid tumour benign21
  • abortion spontaneous20
  • hyperparathyroidism19
  • lacrimation increased19
  • nausea19
  • breast cancer17

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20051
20061
200733
200877
200956
201056
2011263
2012173
201382
201414
201517
201620
20176
201829
201949
202014
202150
20228
20231
20243
20252
20265

Recalls

1 FDA enforcement reports for this application.

  • Mar 11, 2016 · Class III · Terminated

    Labeling: Label Error on Declared Strength

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1 on PubMed

Sponsor: Jubilant · Also marketed as Sodium Iodide I 131

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.